<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100722</url>
  </required_header>
  <id_info>
    <org_study_id>FAME 3</org_study_id>
    <nct_id>NCT02100722</nct_id>
  </id_info>
  <brief_title>A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease</brief_title>
  <acronym>FAME 3</acronym>
  <official_title>Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VZW Cardiovascular Research Center Aalst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Houston Methodist DeBakey Heart and Vascular Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary
      pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided
      percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease
      (CAD) will result in similar outcomes to coronary artery bypass graft surgery (CABG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority
      trial. All patients with multivessel CAD (not involving the left main) will be screened by
      the site's Heart Team (including but not limited to an interventional cardiologist, cardiac
      surgeon and research coordinator). If all agree that the patient can be treated either with
      FFR-guided PCI or CABG, and all inclusion criteria are met and no exclusion criteria are met,
      then the patient will be randomized.

      Baseline clinical, functional, laboratory and electrocardiographic data will be obtained.
      Patients will receive treatment within 4 weeks of randomization. Patients randomized to CABG
      will receive state of the art therapy at the discretion of the local surgeon with a strong
      emphasis on arterial revascularization. Patients undergoing PCI will have FFR measured with a
      St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI
      will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual
      routine. If the FFR is &gt;0.80 then PCI will be deferred.

      All patients will receive medical therapy as per published guidelines. Patients will
      follow-up at 1 and 6 months, and 1 and 3 years with an evaluation of clinical status,
      functional status, medications and events. Follow-up may be extended to 5 years, if funding
      allows.

      Core lab analyses will include formal quantitative coronary angiography (QCA) of the baseline
      angiograms with calculation of the Synergy between Percutaneous Coronary Intervention with
      Taxus and Cardiac Surgery (SYNTAX) score and Functional SYNTAX Score.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>Death, MI, stroke and any repeat revascularization (MACCE) will be evaluated at 1 year, where subjects contribute data from time of randomization until the occurrence of MACCE or one year follow-up, whichever occurs first. Subjects who die or are lost to follow up before 1 year will be censored at their last recorded activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death, MI, and stroke</measure>
    <time_frame>3 years</time_frame>
    <description>Death, MI, and stroke will be evaluated at 3 years, where subjects contribute data from time of enrollment until the occurrence of one of the above events or three year follow-up, whichever occurs first. Subjects who die or are lost to follow up before this time will be censored at their last recorded activity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MACCE</measure>
    <time_frame>2 years, 3 years, 5 years</time_frame>
    <description>Death, MI, stroke and any repeat revascularization (MACCE) rate at 2 years, 3 years and 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>1 year, 2years, 3 years, 5 years</time_frame>
    <description>Death will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <description>MI will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <description>Stroke will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Repeat revascularization</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <description>Any repeat revascularization will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>FFR guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is &gt;0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FFR guided PCI</intervention_name>
    <arm_group_label>FFR guided PCI</arm_group_label>
    <other_name>Fractional Flow Reserve-Guided PCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG</intervention_name>
    <arm_group_label>CABG</arm_group_label>
    <other_name>Coronary Artery Bypass Graft Surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age ≥ 21 years with angina and/or evidence of myocardial ischemia

          -  2. Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each
             of the three major epicardial vessels or major side branches, but not involving left
             main coronary artery, and amenable to revascularization by both PCI and CABG as
             determined by the Heart Team. Patients with a non-dominant right coronary artery may
             be included if only the left anterior descending artery (LAD) and left circumflex have
             ≥50% stenosis

          -  3. Willing and able to provide informed, written consent

        Exclusion Criteria:

          -  1. Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve
             replacement, carotid revascularization)

          -  2. Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support

          -  3. Recent STEMI (&lt;5 days prior to randomization)

          -  4. Ongoing Non STEMI with biomarkers (cardiac troponin) still rising

          -  5. Known left ventricular ejection fraction &lt;30%

          -  6. Life expectancy &lt; 2 years

          -  7. Requiring renal replacement therapy

          -  8. Undergoing evaluation for organ transplantation

          -  9. Participation or planned participation in another clinical trial, except for
             observational registries

          -  10. Pregnancy

          -  11. Inability to take dual antiplatelet therapy for six months

          -  12. Previous CABG

          -  13. Left main disease requiring revascularization

          -  14. Extremely calcified or tortuous vessels precluding FFR measurement

          -  15. Any target lesion with in-stent drug-eluting stent restenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William F Fearon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nico HJ Pijls, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Hospital Eindhoven, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard De Bruyne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VZW Cardiovascular Research Center Aalst</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto VA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexinton VA</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Heart</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Health</name>
      <address>
        <city>Frankston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300 Aalst</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le'Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York PCI Group INC</name>
      <address>
        <city>Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk University and University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet, Dep of clinical science and education, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wales Heart Research Institute</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire</name>
      <address>
        <city>Coventry And Warwickshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospital NHS Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26386784</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Zimmermann FM, De Bruyne B, Pijls NH, Desai M, Oldroyd KG, Park SJ, Reardon MJ, Wendler O, Woo J, Yeung AC, Fearon WF. Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. Am Heart J. 2015 Oct;170(4):619-626.e2. doi: 10.1016/j.ahj.2015.06.024. Epub 2015 Jul 9.</citation>
    <PMID>26386784</PMID>
  </reference>
  <reference>
    <citation>Zimmermann FM, De Bruyne B, Pijls NHJ, Desai M, Oldroyd KG, Reardon MJ, Wendler O, Woo J, Yeung AC, Fearon WF. A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. Am Heart J. 2019 Aug;214:156-157. doi: 10.1016/j.ahj.2019.04.012. Epub 2019 Apr 29.</citation>
    <PMID>31207442</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>William Fearon</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

